FdaApplication
NDA 215151
Identifiers
- fda_app_no: NDA215151
Properties
| Property | Value |
|---|---|
| applicant_name | PHATHOM PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2023-11-01 |
Revenue by product
VOQUEZNA
| Period | Revenue |
|---|---|
| Q1 2026 | $58.3M |
| Q4 2025 | $57.6M |
| Q1 2025 | $28.5M |
| Q4 2024 | $29.7M |
| Q3 2024 | $16.4M |
| Q2 2024 | $7.3M |
| Q1 2024 | $1.9M |
| Q4 2023 | $0.7M |
| Q3 2023 | $0.0M |
| Q2 2023 | $0.0M |
| Q1 2023 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| VOQUEZNA | VONOPRAZAN FUMARATE | EQ 10MG BASE | TABLET;ORAL |
| VOQUEZNA | VONOPRAZAN FUMARATE | EQ 20MG BASE | TABLET;ORAL |
2 products